Biomarkers in cardiogenic shock.

Area of Science:

• Cardiovascular Medicine
• Biomarker Discovery
• Critical Care

Background:

• Cardiogenic shock (CS) is a life-threatening condition characterized by cardiac dysfunction, hypoperfusion, and organ injury.
• Established biomarkers like lactate and troponins are used for CS diagnosis and monitoring.
• The complex pathophysiology involves hemodynamic instability, inflammation, and multi-organ dysfunction, necessitating advanced assessment tools.

Purpose of the Study:

• To review the clinical utility of various biomarkers in the diagnosis, monitoring, and risk stratification of cardiogenic shock.
• To discuss the role of established and novel biomarkers in understanding CS pathophysiology and predicting patient outcomes.
• To highlight biomarkers for organ injury, dysfunction, and metabolism in the context of CS management.

Main Methods:

• Literature review focusing on the clinical application of biomarkers in cardiogenic shock.
• Analysis of established markers (lactate, troponins, renal function) and novel markers (GDF-15, sST2, DPP).
• Evaluation of biomarker prognostic properties for mortality risk prediction in CS patients.

Main Results:

• Established biomarkers are crucial for initial CS diagnosis and monitoring.
• Novel biomarkers (GDF-15, sST2, DPP) show promise in elucidating CS pathophysiology and improving risk stratification.
• Biomarkers of organ injury, dysfunction, and metabolism are essential for comprehensive CS management.

Conclusions:

• Biomarkers play a vital role in the clinical management of cardiogenic shock, from diagnosis to risk prediction.
• Integrating novel biomarkers can enhance our understanding of CS complexity and guide therapeutic strategies.
• Prognostic biomarker data is critical for effective mortality risk stratification in patients with cardiogenic shock.